Consistent with this hypothesis, a previous study in the Hyp mouse model of XLH (26) used a Col2.3-cre to delete Fgf23 in osteoblasts and achieved a similar correction of hypophosphatemia but complete corrections of FGF23 levels, bone growth, and bone morphology. This evidence concerns the gene FGF23 and hypophosphatemia.